Companies seek second GLP-1 revolution-in pill form

Science. 2025 Apr 18;388(6744):241-242. doi: 10.1126/science.ady2624. Epub 2025 Apr 17.

Abstract

Smaller, easier to make drug compounds could treat obesity and diabetes with fewer side effects.

Publication types

  • News

MeSH terms

  • Anti-Obesity Agents* / adverse effects
  • Anti-Obesity Agents* / chemistry
  • Anti-Obesity Agents* / therapeutic use
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucagon-Like Peptide 1* / administration & dosage
  • Glucagon-Like Peptide 1* / analogs & derivatives
  • Glucagon-Like Peptide 1* / therapeutic use
  • Humans
  • Hypoglycemic Agents* / administration & dosage
  • Hypoglycemic Agents* / adverse effects
  • Hypoglycemic Agents* / therapeutic use
  • Obesity* / drug therapy
  • Piperidines / adverse effects
  • Piperidines / therapeutic use

Substances

  • Anti-Obesity Agents
  • Glucagon-Like Peptide 1
  • Hypoglycemic Agents
  • Benzimidazoles
  • Piperidines
  • danuglipron